Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

No, Atlanta is not experiencing an outbreak of HIV, although the rates of new diagnosis are considered high in some ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

Central Florida faces one of the highest HIV prevalence rates in the nation, with over 14,000 individuals currently living with the virus. Approximately 13% of those infected are unaware of their ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

In HIV-1-infected patients with extensive drug resistance, the optimization of background antiretroviral therapy is essential when changing drugs after treatment failure. The genotypic sensitivity ...

University of Michigan researchers have uncovered new details of the process that HIV uses to hijack cells’ transportation systems for its own survival.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

JACKSON, Miss. (WLBT) -A new breakthrough drug for HIV Prevention has been approved by the FDA. The drug is called “Yeztugo” ...

University of Michigan researchers have uncovered new details of the process that HIV uses to hijack cells' transportation ...